Literature DB >> 17705576

Lipoprotein-associated phospholipase A(2) : review of its role as a marker and a potential participant in coronary endothelial dysfunction.

Shahar Lavi1, Ronit Lavi, Joseph P McConnell, Lilach O Lerman, Amir Lerman.   

Abstract

The role of inflammation in atherosclerosis continues to emerge. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), a novel plasma biomarker, circulates in the blood bound mainly to low-density lipoprotein (LDL) and promotes vascular inflammation. Several epidemiological studies have shown that circulating levels of Lp-PLA(2) are an independent risk factor for cardiovascular events. Recent studies demonstrate that Lp-PLA(2) is also associated with endothelial dysfunction and early atherosclerosis. This review provides an overview of these studies, suggests plausible mechanisms for the association between endothelial dysfunction and Lp-PLA(2), and highlights future potential therapies.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17705576     DOI： 10.1007/BF03256243

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN： 1177-1062            Impact factor:   4.074


  68 in total

Review 1.  The clinical implications of endothelial dysfunction.

Authors:  Michael E Widlansky; Noyan Gokce; John F Keaney; Joseph A Vita
Journal:  J Am Coll Cardiol       Date:  2003-10-01       Impact factor: 24.094

2.  Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction.

Authors:  J A Suwaidi; S Hamasaki; S T Higano; R A Nishimura; D R Holmes; A Lerman
Journal:  Circulation       Date:  2000-03-07       Impact factor: 29.690

3.  Lysophosphatidylcholine increases the secretion of matrix metalloproteinase 2 through the activation of NADH/NADPH oxidase in cultured aortic endothelial cells.

Authors:  N Inoue; S Takeshita; D Gao; T Ishida; S Kawashima; H Akita; R Tawa; H Sakurai; M Yokoyama
Journal:  Atherosclerosis       Date:  2001-03       Impact factor: 5.162

Review 4.  Phospholipase A(2) in vascular disease.

Authors:  E Hurt-Camejo; G Camejo; H Peilot; K Oörni; P Kovanen
Journal:  Circ Res       Date:  2001-08-17       Impact factor: 17.367

5.  Renal vascular function in hypercholesterolemia is preserved by chronic antioxidant supplementation.

Authors:  John M Stulak; Amir Lerman; Martin Rodriguez Porcel; James A Caccitolo; J Carlos Romero; Hartzell V Schaff; Claudio Napoli; Lilach O Lerman
Journal:  J Am Soc Nephrol       Date:  2001-09       Impact factor: 10.121

6.  Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study.

Authors:  Carlos Iribarren; Myron D Gross; Jeanne A Darbinian; David R Jacobs; Stephen Sidney; Catherine M Loria
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-10-21       Impact factor: 8.311

7.  Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma.

Authors:  Irene Gazi; Evangelia S Lourida; Theodosios Filippatos; Vasilis Tsimihodimos; Moses Elisaf; Alexandros D Tselepis
Journal:  Clin Chem       Date:  2005-10-13       Impact factor: 8.327

8.  Effect of lysophosphatidylcholine on vasomotor functions of porcine coronary arteries.

Authors:  Rakesh Safaya; Hong Chai; Panagiotis Kougias; Peter Lin; Alan Lumsden; Qizhi Yao; Changyi Chen
Journal:  J Surg Res       Date:  2005-06-15       Impact factor: 2.192

9.  Potential role for mast cell tryptase in recruitment of inflammatory cells to endothelium.

Authors:  Maureen C Meyer; Michael H Creer; Jane McHowat
Journal:  Am J Physiol Cell Physiol       Date:  2005-08-03       Impact factor: 4.249

10.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.

Authors:  James A de Lemos; Michael A Blazing; Stephen D Wiviott; Eldrin F Lewis; Keith A A Fox; Harvey D White; Jean-Lucien Rouleau; Terje R Pedersen; Laura H Gardner; Robin Mukherjee; Karen E Ramsey; Joanne Palmisano; David W Bilheimer; Marc A Pfeffer; Robert M Califf; Eugene Braunwald
Journal:  JAMA       Date:  2004-08-30       Impact factor: 56.272
View more
  6 in total

1.  Long-term darapladib use does not affect coronary plaque composition assessed using multimodality intravascular imaging modalities: a randomized-controlled study.

Authors:  Woong Gil Choi; Megha Prasad; Ryan Lennon; Rajiv Gulati; Abhiram Prasad; Lilach O Lerman; Amir Lerman
Journal:  Coron Artery Dis       Date:  2018-03       Impact factor: 1.439

Review 2.  Role of lipoprotein-associated phospholipase A2 in atherosclerosis.

Authors:  Shahar Lavi; Joerg Herrmann; Ronit Lavi; Joseph P McConnell; Lilach O Lerman; Amir Lerman
Journal:  Curr Atheroscler Rep       Date:  2008-06       Impact factor: 5.113

Review 3.  Predicting the risk of cardiovascular disease: where does lipoprotein-associated phospholipase A(2) fit in?

Authors:  Natalie Khuseyinova; Wolfgang Koenig
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

4.  Expression of lipoprotein-associated phospholipase A(2) in carotid artery plaques predicts long-term cardiac outcome.

Authors:  Joerg Herrmann; Dallit Mannheim; Christine Wohlert; Daniele Versari; Fredric B Meyer; Joseph P McConnell; Mario Gössl; Lilach O Lerman; Amir Lerman
Journal:  Eur Heart J       Date:  2009-08-17       Impact factor: 29.983

5.  The Beneficial Effects of Alpha Lipoic Acid Supplementation on Lp-PLA2 Mass and Its Distribution between HDL and apoB-Containing Lipoproteins in Type 2 Diabetic Patients: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Nima Baziar; Ensieh Nasli-Esfahani; Kurosh Djafarian; Mostafa Qorbani; Mehdi Hedayati; Mahshid Abd Mishani; Zeinab Faghfoori; Najva Ahmaripour; Saeed Hosseini
Journal:  Oxid Med Cell Longev       Date:  2020-03-09       Impact factor: 6.543

6.  Endothelial Dysfunction in Children With Obstructive Sleep Apnea Is Associated With Elevated Lipoprotein-Associated Phospholipase A2 Plasma Activity Levels.

Authors:  Leila Kheirandish-Gozal; Mona F Philby; Zhuanghong Qiao; Abdelnaby Khalyfa; David Gozal
Journal:  J Am Heart Assoc       Date:  2017-02-09       Impact factor: 5.501
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.